{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+T+Cell%2C+Peripheral&page=3", "query": { "condition": "Lymphoma, T Cell, Peripheral", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 382, "total_pages": 39, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+T+Cell%2C+Peripheral&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+T+Cell%2C+Peripheral&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T03:45:55.710Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03278782", "title": "Study of Pembrolizumab (MK-3475) in Combination With Romidepsin", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Anaplastic Large Cell Lymphoma", "Recurrent Angioimmunoblastic T-Cell Lymphoma", "Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma", "Recurrent Mycosis Fungoides", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory Anaplastic Large Cell Lymphoma", "Refractory Angioimmunoblastic T-Cell Lymphoma", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Refractory Mycosis Fungoides", "Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Romidepsin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2017-11-14", "completion_date": "2027-07-31", "has_results": true, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-05T03:45:55.710Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03278782" }, { "nct_id": "NCT04334174", "title": "Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T Cell Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-05-29", "completion_date": "2023-02-01", "has_results": false, "last_update_posted_date": "2023-02-03", "last_synced_at": "2026-10-05T03:45:55.710Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04334174" }, { "nct_id": "NCT00003962", "title": "Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": null, "start_date": "1998-04", "completion_date": "2000-06", "has_results": false, "last_update_posted_date": "2014-05-02", "last_synced_at": "2026-10-05T03:45:55.710Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003962" }, { "nct_id": "NCT01482962", "title": "Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed Peripheral T-Cell Lymphoma", "Refractory Peripheral T-Cell Lymphoma" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Pralatrexate", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 271, "start_date": "2012-06-11", "completion_date": "2017-12-18", "has_results": true, "last_update_posted_date": "2018-07-31", "last_synced_at": "2026-10-05T03:45:55.710Z", "location_count": 24, "location_summary": "Birmingham, Alabama • La Jolla, California • Orlando, Florida + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01482962" }, { "nct_id": "NCT01614197", "title": "A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoblastic Leukemia, Acute, Childhood", "Lymphoblastic Lymphoma", "Peripheral T-cell Lymphoma" ], "interventions": [ { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 16, "start_date": "2015-07-03", "completion_date": "2020-09-04", "has_results": true, "last_update_posted_date": "2023-07-27", "last_synced_at": "2026-10-05T03:45:55.710Z", "location_count": 25, "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01614197" }, { "nct_id": "NCT04068597", "title": "Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Haematological Malignancy", "Acute Myeloid Leukemia", "Non Hodgkin Lymphoma", "Multiple Myeloma", "Higher-risk Myelodysplastic Syndrome", "Peripheral T Cell Lymphoma" ], "interventions": [ { "name": "CCS1477", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Elranatamab", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CellCentric Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2019-08-09", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-10-05T03:45:55.710Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Indianapolis, Indiana • Bethesda, Maryland + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04068597" }, { "nct_id": "NCT05377827", "title": "Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-Cell Non-Hodgkin Lymphoma", "Acute Myeloid Leukemia", "Angioimmunoblastic T-cell Lymphoma", "Enteropathy-Associated T-Cell Lymphoma", "Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma", "Peripheral T Cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Adult T Cell Leukemia", "Adult T Cell Lymphoma", "T Cell Prolymphocytic Leukemia", "Extranodal NK/T-cell Lymphoma", "Transformed Mycosis Fungoides", "Sezary Syndrome", "Primary Cutaneous Gamma-Delta T-Cell Lymphoma", "Hepatosplenic T-cell Lymphoma" ], "interventions": [ { "name": "WU-CART-007", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-10-10", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-05T03:45:55.710Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05377827" }, { "nct_id": "NCT04712864", "title": "Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-Cell Lymphoma", "Peripheral T-Cell Lymphoma Refractory", "Cutaneous T-Cell Lymphoma Refractory", "Cutaneous T-Cell Lymphoma Recurrent", "Peripheral T-Cell Lymphoma Recurrent" ], "interventions": [ { "name": "LB1901", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Legend Biotech USA Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-09-13", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2023-10-03", "last_synced_at": "2026-10-05T03:45:55.710Z", "location_count": 4, "location_summary": "Rochester, Minnesota • Houston, Texas • Seattle, Washington + 1 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04712864" }, { "nct_id": "NCT01008462", "title": "Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Prolymphocytic Leukemia", "Hypodiploidy", "Loss of Chromosome 17p", "Plasma Cell Leukemia", "Progression of Multiple Myeloma or Plasma Cell Leukemia", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Non-Hodgkin Lymphoma", "Recurrent Childhood Hodgkin Lymphoma", "Recurrent Childhood Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Plasma Cell Myeloma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Non-Hodgkin Lymphoma", "Refractory Plasma Cell Myeloma", "Refractory Small Lymphocytic Lymphoma", "t(14;16)", "t(4;14)", "T-Cell Prolymphocytic Leukemia", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Allogeneic Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 16, "start_date": "2010-03-18", "completion_date": "2018-06-30", "has_results": true, "last_update_posted_date": "2019-06-11", "last_synced_at": "2026-10-05T03:45:55.710Z", "location_count": 2, "location_summary": "Seattle, Washington • Milwaukee, Wisconsin", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01008462" }, { "nct_id": "NCT06561048", "title": "Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Angioimmunoblastic T-cell Lymphoma", "Follicular T-Cell Lymphoma", "Nodal Peripheral T-Cell Lymphoma With TFH Phenotype", "Systemic Anaplastic Large Cell Lymphoma", "Lymphoma, T-Cell, Peripheral", "Lymphoma, T-Cell" ], "interventions": [ { "name": "Soquelitinib", "type": "DRUG" }, { "name": "Belinostat", "type": "DRUG" }, { "name": "Pralatrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corvus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2024-10-02", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-05T03:45:55.710Z", "location_count": 24, "location_summary": "Duarte, California • Irvine, California • San Francisco, California + 19 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06561048" } ] }